McGee et al. (2017) also found a lower than expected breast cancer incidence in their study cohort of 509 BRCA1/BRCA2 mutation carriers followed up to 20 years (mean 6.9 years) after ovarian cancer diagnosis. This evidence concerns the gene BRCA1 and ovarian cancer.